Picture loading failed.

Anti-EPCAM;CD3E therapeutic antibody (Pre-made Solitomab biosimilar,Bispecific scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Solitomab (INN; development code MT110) is an artificial bispecific monoclonal antibody that is being investigated as an anti-cancer drug. It is a fusion protein consisting of two single-chain variable fragments (scFvs) of different antibodies on a single peptide chain of about 55 kilodaltons. One of the scFvs binds to T cells via the CD3 receptor, and the other to EpCAM as a tumor antigen against gastrointestinal, lung, and other cancers.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-528-1mg 1mg 3090
GMP-Bios-ab-528-10mg 10mg 21890
GMP-Bios-ab-528-100mg 100mg 148000
GMP-Bios-ab-528-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-EPCAM;CD3E therapeutic antibody (Pre-made Solitomab biosimilar,Bispecific scFv)
INN Name Solitomab
TargetEPCAM;CD3E
FormatBispecific scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2011
Year Recommended2012
CompaniesMicromet Inc;Amgen
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours
Development Techna